BCL2 and acute lymphoblastic leukemia: Despite the strong rationale for targeting BCL-2 in HR BCP-ALL, the response of leukemic cells to VEN is heterogeneous [19, 20] and VEN monotherapy is frequently insufficient to completely eliminate leukemic cells [18, 21–23].